
BioMarin Revenue Surges 18% to $2.9B on VOXZOGO Boom
BioMarin Pharmaceutical Inc.Description
What this story covers
BioMarin reported $2.9B revenue in 2024, up 18%, led by VOXZOGO's 57% growth to $735M. Strong liquidity at $1.7B supports pipeline expansions amid regulatory and competitive risks. Net income rose 155% to $427M, signaling profitability shift.
Story snapshot
CompanyBioMarin Pharmaceutical Inc.
TickerBMRN
VariantStandard detailed
Duration13:46
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0001048477-25-000007
Full Story Script
Content not available for this story.